World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision

Borwin Bandelow, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans Jurgen Möller, Christer Allgulander, José Ayuso-Gutierrez, David S. Baldwin, Robertas Bunevicius, Giovanni Cassano, Naomi Fineberg, Loes Gabriels, Ian Hindmarch, Hisanobu Kaiya, Donald F. Klein, Malcolm Lader, Yves Lecrubier, Jean Pierre Lépine, Michael R. Liebowitz, Juan José Lopez-IborDonatella Marazziti, Euripedes C. Miguel, Kang Seob Oh, Maurice Preter, Rainer Rupprecht, Mitsumoto Sato, Vladan Starcevic, Dan J. Stein, Michael van Ameringen, Johann Vega

Research output: Contribution to journalArticle

471 Citations (Scopus)

Abstract

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

Original languageEnglish (US)
Pages (from-to)248-312
Number of pages65
JournalWorld Journal of Biological Psychiatry
Volume9
Issue number4
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Biological Psychiatry
Post-Traumatic Stress Disorders
Anxiety
Pharmacology
Guidelines
Obsessive-Compulsive Disorder
Anti-Anxiety Agents
Serotonin Uptake Inhibitors
Anxiety Disorders
Therapeutics
Behavior Therapy
Tricyclic Antidepressive Agents
Cognitive Therapy
Advisory Committees
Calcium Channels
Secondary Prevention
Benzodiazepines
Substance-Related Disorders
Psychiatry
Publications

Keywords

  • Anticonvulsants
  • Antidepressants
  • Antipsychotics
  • Anxiety disorders
  • Anxiolytics
  • Benzodiazepines
  • Cognitive behaviour therapy
  • Evidence-based guidelines
  • Generalized anxiety disorder
  • Obsessive-compulsive disorder
  • Panic disorder
  • Post-traumatic stress disorder
  • Simple phobia
  • SNRI
  • Social phobia
  • SSRI
  • Treatment

ASJC Scopus subject areas

  • Biological Psychiatry
  • Psychiatry and Mental health

Cite this

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision. / Bandelow, Borwin; Zohar, Joseph; Hollander, Eric; Kasper, Siegfried; Möller, Hans Jurgen; Allgulander, Christer; Ayuso-Gutierrez, José; Baldwin, David S.; Bunevicius, Robertas; Cassano, Giovanni; Fineberg, Naomi; Gabriels, Loes; Hindmarch, Ian; Kaiya, Hisanobu; Klein, Donald F.; Lader, Malcolm; Lecrubier, Yves; Lépine, Jean Pierre; Liebowitz, Michael R.; Lopez-Ibor, Juan José; Marazziti, Donatella; Miguel, Euripedes C.; Oh, Kang Seob; Preter, Maurice; Rupprecht, Rainer; Sato, Mitsumoto; Starcevic, Vladan; Stein, Dan J.; van Ameringen, Michael; Vega, Johann.

In: World Journal of Biological Psychiatry, Vol. 9, No. 4, 2008, p. 248-312.

Research output: Contribution to journalArticle

Bandelow, B, Zohar, J, Hollander, E, Kasper, S, Möller, HJ, Allgulander, C, Ayuso-Gutierrez, J, Baldwin, DS, Bunevicius, R, Cassano, G, Fineberg, N, Gabriels, L, Hindmarch, I, Kaiya, H, Klein, DF, Lader, M, Lecrubier, Y, Lépine, JP, Liebowitz, MR, Lopez-Ibor, JJ, Marazziti, D, Miguel, EC, Oh, KS, Preter, M, Rupprecht, R, Sato, M, Starcevic, V, Stein, DJ, van Ameringen, M & Vega, J 2008, 'World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision', World Journal of Biological Psychiatry, vol. 9, no. 4, pp. 248-312. https://doi.org/10.1080/15622970802465807
Bandelow, Borwin ; Zohar, Joseph ; Hollander, Eric ; Kasper, Siegfried ; Möller, Hans Jurgen ; Allgulander, Christer ; Ayuso-Gutierrez, José ; Baldwin, David S. ; Bunevicius, Robertas ; Cassano, Giovanni ; Fineberg, Naomi ; Gabriels, Loes ; Hindmarch, Ian ; Kaiya, Hisanobu ; Klein, Donald F. ; Lader, Malcolm ; Lecrubier, Yves ; Lépine, Jean Pierre ; Liebowitz, Michael R. ; Lopez-Ibor, Juan José ; Marazziti, Donatella ; Miguel, Euripedes C. ; Oh, Kang Seob ; Preter, Maurice ; Rupprecht, Rainer ; Sato, Mitsumoto ; Starcevic, Vladan ; Stein, Dan J. ; van Ameringen, Michael ; Vega, Johann. / World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision. In: World Journal of Biological Psychiatry. 2008 ; Vol. 9, No. 4. pp. 248-312.
@article{5d11072aa87941f1a8dedd356682a181,
title = "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision",
abstract = "In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.",
keywords = "Anticonvulsants, Antidepressants, Antipsychotics, Anxiety disorders, Anxiolytics, Benzodiazepines, Cognitive behaviour therapy, Evidence-based guidelines, Generalized anxiety disorder, Obsessive-compulsive disorder, Panic disorder, Post-traumatic stress disorder, Simple phobia, SNRI, Social phobia, SSRI, Treatment",
author = "Borwin Bandelow and Joseph Zohar and Eric Hollander and Siegfried Kasper and M{\"o}ller, {Hans Jurgen} and Christer Allgulander and Jos{\'e} Ayuso-Gutierrez and Baldwin, {David S.} and Robertas Bunevicius and Giovanni Cassano and Naomi Fineberg and Loes Gabriels and Ian Hindmarch and Hisanobu Kaiya and Klein, {Donald F.} and Malcolm Lader and Yves Lecrubier and L{\'e}pine, {Jean Pierre} and Liebowitz, {Michael R.} and Lopez-Ibor, {Juan Jos{\'e}} and Donatella Marazziti and Miguel, {Euripedes C.} and Oh, {Kang Seob} and Maurice Preter and Rainer Rupprecht and Mitsumoto Sato and Vladan Starcevic and Stein, {Dan J.} and {van Ameringen}, Michael and Johann Vega",
year = "2008",
doi = "10.1080/15622970802465807",
language = "English (US)",
volume = "9",
pages = "248--312",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision

AU - Bandelow, Borwin

AU - Zohar, Joseph

AU - Hollander, Eric

AU - Kasper, Siegfried

AU - Möller, Hans Jurgen

AU - Allgulander, Christer

AU - Ayuso-Gutierrez, José

AU - Baldwin, David S.

AU - Bunevicius, Robertas

AU - Cassano, Giovanni

AU - Fineberg, Naomi

AU - Gabriels, Loes

AU - Hindmarch, Ian

AU - Kaiya, Hisanobu

AU - Klein, Donald F.

AU - Lader, Malcolm

AU - Lecrubier, Yves

AU - Lépine, Jean Pierre

AU - Liebowitz, Michael R.

AU - Lopez-Ibor, Juan José

AU - Marazziti, Donatella

AU - Miguel, Euripedes C.

AU - Oh, Kang Seob

AU - Preter, Maurice

AU - Rupprecht, Rainer

AU - Sato, Mitsumoto

AU - Starcevic, Vladan

AU - Stein, Dan J.

AU - van Ameringen, Michael

AU - Vega, Johann

PY - 2008

Y1 - 2008

N2 - In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

AB - In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

KW - Anticonvulsants

KW - Antidepressants

KW - Antipsychotics

KW - Anxiety disorders

KW - Anxiolytics

KW - Benzodiazepines

KW - Cognitive behaviour therapy

KW - Evidence-based guidelines

KW - Generalized anxiety disorder

KW - Obsessive-compulsive disorder

KW - Panic disorder

KW - Post-traumatic stress disorder

KW - Simple phobia

KW - SNRI

KW - Social phobia

KW - SSRI

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=54949154218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949154218&partnerID=8YFLogxK

U2 - 10.1080/15622970802465807

DO - 10.1080/15622970802465807

M3 - Article

C2 - 18949648

AN - SCOPUS:54949154218

VL - 9

SP - 248

EP - 312

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 4

ER -